Viewpoint
Cholinergic mechanisms in learning, memory and dementia: a review of recent evidence

https://doi.org/10.1016/0166-2236(91)90117-DGet rights and content

Abstract

The discovery in the late 1970s that cholinergic neurons in the basal forebrain degenerate in Alzheimer's disease (AD) greatly accelerated research on the role of cholinergic mechanisms in learning and memory. As is often the case in science, the early enthusiasm for the cholinergic hypothesis has been tempered by the results of subsequent research. Although there is substantial pharmacological evidence that unspecified cholinergic systems in the brain play important roles in some forms of learning and memory, recent findings in humans indicate that antimuscarinic drugs do not model the deficits seen in AD. In addition, the goal of elucidating the functions of these basal forebrain neurons in animals has proved to be difficult and is yet to be achieved. Despite substantial effort, therefore, the cognitive and behavioral consequences of cholinergic pathology in AD remain unknown. Under these circumstances, attempts to develop cholinergic pharmacotherapies for these deficits in AD are based on questionable assumptions.

References (47)

  • T.G. Aigner et al.

    Behav. Neural Biol.

    (1986)
  • W.W. Beatty et al.

    Behav. Neural Biol.

    (1986)
  • W.W. Beatty et al.

    Neurobiol. Aging

    (1988)
  • D. Collerton

    Neuroscience

    (1986)
  • K. Semba et al.
  • A. Rotter

    Brain Res. Rev.

    (1979)
  • A. Rotter

    Brain Res. Rev.

    (1979)
  • D.C. Mash et al.

    Neuroscience

    (1986)
  • R.T. Bartus

    Pharmacol. Biochem. Behav.

    (1985)
  • B. Dubois et al.

    Brain Res.

    (1985)
  • B.J. Everitt

    Neuroscience

    (1987)
  • D.J. Hepler et al.

    Brain Res.

    (1985)
  • B.J. Knowlton et al.

    Brain Res.

    (1985)
  • C.L. Murray et al.

    Neuroscience

    (1985)
  • S.B. Dunnett et al.

    Brain Res.

    (1982)
  • S.B. Dunnett

    Neuroscience

    (1985)
  • T.W. Robbins

    Neuroscience

    (1989)
  • A.I. Markowska et al.

    Behav. Neural Biol.

    (1990)
  • A. Levy et al.

    Brain Res.

    (1984)
  • S.R. McGurk et al.

    Neuroscience

    (1987)
  • J.J. Hagan et al.
  • J.A. Deutsch

    Science

    (1971)
  • E.K. Perry

    Br. Med. J.

    (1978)
  • Cited by (552)

    • Critical role of hippocampal muscarinic acetylcholine receptors on memory reconsolidation in mice

      2021, Neurobiology of Learning and Memory
      Citation Excerpt :

      It is known that there are conditions (e.g. the presentation of a specific reminder of the stored experience) or requirements necessary for the reconsolidation process to take place such as: the strength of the training (Boccia et al., 2004; Suzuki et al., 2004), the age of memory (Boccia, Blake, Acosta, & Baratti, 2006; Milekic & Alberini, 2002), the duration of CS (Pedreira & Maldonado, 2003), the mismatch between what is expected and what actually happens (Exton-McGuinness, Lee, & Reichelt, 2015; Mackintosh, 1975; Pearce & Bouton, 2001; Pedreira, Pérez-Cuesta, & Maldonado, 2004) [for a review see, Fernández, Boccia et al., 2016; Fernández, Bavassi et al., 2016]. Over the years, many studies have shown that cholinergic antagonists were responsible for the behavioral impairment observed in different learning tasks (Boccia et al., 2004, 2006; Decker & McGaugh, 1991; Fibiger, 1991; Gallagher & Colombo, 1995). Moreover, there is no discussion on the necessity of endogenous ACh in the different stages of memory processes such as consolidation, retrieval, extinction and memory reconsolidation in order to take place (Boccia, Blake, Acosta, & Baratti, 2003, 2004, 2009).

    • Exercise, cognitive creativity, and dementia

      2020, Diagnosis and Management in Dementia: The Neuroscience of Dementia, Volume 1
    • In Vivo Pharmacological Comparison of TAK-071, a Positive Allosteric Modulator of Muscarinic M<inf>1</inf> Receptor, and Xanomeline, an Agonist of Muscarinic M<inf>1</inf>/M<inf>4</inf> Receptor, in Rodents

      2019, Neuroscience
      Citation Excerpt :

      Therefore, the development of new drugs with better efficacy is warranted. Cholinergic neurotransmission in the cerebral cortex and hippocampus is a key mediator of learning and memory (Fibiger, 1991), and cholinergic dysfunction is commonly reported in patients with AD, DLB, and schizophrenia. In AD and DLB, the basal forebrain cholinergic neurons that innervate the cerebral cortex and hippocampus are selectively degenerated (Whitehouse et al., 1982; McKeith et al., 1996).

    View all citing articles on Scopus
    View full text